CompareMarketResearchRequest a sample
Home / Healthcare / Cell-Free DNA Testing Transplant

Healthcare · Market report

Cell-Free DNA Testing Transplant Market Size, Share and Forecast 2026-2036

The global cell-free DNA testing transplant market is worth USD 462 mn in 2026 and is forecast to reach USD 1.2 bn by 2036, growing at a 10.0% CAGR. United States is the largest country market and Kidney is the largest by organ segment.

USD 462 mnMarket size 2026
USD 1.2 bnForecast 2036
10.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global cell-free DNA testing transplant market is worth USD 462 mn in 2026 and is forecast to reach USD 1.2 bn by 2036, growing at a 10.0% CAGR. United States is the largest country market and Kidney is the largest by organ segment.

ScopeBlood tests that measure donor-derived cell-free DNA to detect rejection of transplanted kidneys, hearts, lungs and livers, sold as laboratory-developed or cleared services to transplant centres.
IndustryHealthcare
Value 2025USD 420 mn
Value 2026USD 462 mn
Value 2036USD 1.2 bn
CAGR 2026-203610.0%
Volume 2026367 thousand tests
Volume 20361,052 thousand tests
Average price 2026USD 1,260 per test
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Cell-Free DNA Testing Transplant market size and forecast, 2026-2036

Exhibit 1The global cell-free DNA testing transplant market is forecast to grow from USD 462 mn in 2026 to USD 1.2 bn by 2036, more than doublingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 10.0%
Cell-Free DNA Testing Transplant market value, 2025 to 2036Market value by year. 2025: USD 420 mn; 2026: USD 462 mn; 2027: USD 508 mn; 2028: USD 559 mn; 2029: USD 615 mn; 2030: USD 676 mn; 2031: USD 744 mn; 2032: USD 818 mn; 2033: USD 900 mn; 2034: USD 990 mn; 2035: USD 1.1 bn; 2036: USD 1.2 bn. Compound annual growth rate 2026 to 2036: 10.0%.2025462 mn2026744 mn20311.2 bn203610.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 462 mn
2027USD 508 mn
2028USD 559 mn
2029USD 615 mn
2030USD 676 mn
2031USD 744 mn
2032USD 818 mn
2033USD 900 mn
2034USD 990 mn
2035USD 1.1 bn
2036USD 1.2 bn

Cell-Free DNA Testing Transplant market segmentation

By organ

Exhibit 2Kidney is the largest segment by organ, with 66.0% of 2026 revenueEstimated share of 2026 global revenue, by organ
Cell-Free DNA Testing Transplant market share by organ, 2026Share of 2026 revenue by organ. Kidney: 66.0%; Heart: 17.0%; Lung: 9.0%; Liver and other: 8.0%.Kidney66.0%Heart17.0%Lung9.0%Liver and other8.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Kidney66.0%58.6%USD 305 mn8.7%
Heart17.0%19.8%USD 79 mn11.7%
Lung9.0%11.5%USD 42 mn12.7%
Liver and other8.0%10.2%USD 37 mn12.7%

By testing purpose

Exhibit 3Surveillance monitoring adds the most revenue by testing purpose, growing from USD 268 mn in 2026 to USD 727 mn by 2036Estimated revenue in USD by testing purpose, 2026 and 2036 forecast
Cell-Free DNA Testing Transplant market by testing purpose, 2026 and 2036Revenue by testing purpose in 2026 and 2036. Surveillance monitoring: USD 268 mn in 2026, USD 727 mn in 2036, change +171%; For-cause testing: USD 139 mn in 2026, USD 313 mn in 2036, change +126%; Clinical trials and research: USD 55 mn in 2026, USD 157 mn in 2036, change +184%.20262036 forecastChangeSurveillance monitoring+171%268 mn727 mnFor-cause testing+126%139 mn313 mnClinical trials and research+184%55 mn157 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Surveillance monitoring58.0%60.7%USD 268 mn10.5%
For-cause testing30.0%26.2%USD 139 mn8.5%
Clinical trials and research12.0%13.1%USD 55 mn11.0%

By technology

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Next-generation sequencing48.0%50.0%USD 222 mn10.4%
Digital PCR30.0%30.0%USD 139 mn10.0%
Targeted panels22.0%20.0%USD 102 mn9.0%

By biomarker

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Donor-derived cell-free DNA72.0%66.0%USD 333 mn9.1%
Methylation markers14.0%18.0%USD 65 mn12.8%
Other markers14.0%16.0%USD 65 mn11.5%

By buyer

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Transplant centers58.0%54.0%USD 268 mn9.2%
Reference labs30.0%32.0%USD 139 mn10.7%
Research institutes12.0%14.0%USD 55 mn11.7%

Top 25 countries for cell-free DNA testing transplant by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 98.0% of 2026 revenue and the 25 countries below together hold 99.6%.

Exhibit 4United States is the largest country market at USD 360 mn in 2026, and the three largest countries hold 85.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Cell-Free DNA Testing Transplant market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 360 mn, 78.0%; Germany: USD 18 mn, 4.0%; United Kingdom: USD 14 mn, 3.0%; France: USD 14 mn, 3.0%; Australia: USD 9.2 mn, 2.0%; Canada: USD 9.2 mn, 2.0%; Japan: USD 9.2 mn, 2.0%; Spain: USD 6.9 mn, 1.5%; Italy: USD 6.9 mn, 1.5%; Brazil: USD 4.6 mn, 1.0%.United States360 mn 78.0%Germany18 mn 4.0%United Kingdom14 mn 3.0%France14 mn 3.0%Australia9.2 mn 2.0%Canada9.2 mn 2.0%Japan9.2 mn 2.0%Spain6.9 mn 1.5%Italy6.9 mn 1.5%Brazil4.6 mn 1.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 360 mn78.0%USD 947 mn10.1%
2GermanyUSD 18 mn4.0%USD 44 mn9.2%
3United KingdomUSD 14 mn3.0%USD 35 mn9.6%
4FranceUSD 14 mn3.0%USD 34 mn9.2%
5AustraliaUSD 9.2 mn2.0%USD 24 mn10.0%
6CanadaUSD 9.2 mn2.0%USD 23 mn9.4%
7JapanUSD 9.2 mn2.0%USD 22 mn8.8%
8SpainUSD 6.9 mn1.5%USD 17 mn9.2%
9ItalyUSD 6.9 mn1.5%USD 16 mn8.4%
10BrazilUSD 4.6 mn1.0%USD 13 mn11.1%
11NetherlandsUSD 1.1 mn0.2%USD 2.6 mn9.5%
12SwitzerlandUSD 0.83 mn0.2%USD 2.2 mn10.0%
13SwedenUSD 0.74 mn0.2%USD 1.9 mn10.0%
14BelgiumUSD 0.74 mn0.2%USD 1.8 mn9.3%
15AustriaUSD 0.60 mn0.1%USD 1.6 mn10.0%
16TaiwanUSD 0.55 mn0.1%USD 1.7 mn11.7%
17DenmarkUSD 0.55 mn0.1%USD 1.3 mn9.1%
18PolandUSD 0.42 mn0.09%USD 1.1 mn10.0%
19IsraelUSD 0.37 mn0.08%USD 0.96 mn10.0%
20SingaporeUSD 0.37 mn0.08%USD 0.96 mn10.0%
21South KoreaUSD 0.28 mn0.06%USD 0.72 mn10.0%
22ChinaUSD 0.23 mn0.05%USD 0.48 mn7.6%
23MexicoUSD 0.18 mn0.04%USD 0.48 mn10.0%
24TurkeyUSD 0.18 mn0.04%USD 0.48 mn10.0%
25Saudi ArabiaUSD 0.18 mn0.04%USD 0.48 mn10.0%
Rest of worldUSD 1.9 mn0.4%USD 6.5 mn12.8%
Exhibit 5United States and Germany account for 83% of the USD 736 mn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Cell-Free DNA Testing Transplant market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 462 mn. United States: +USD 586 mn; Germany: +USD 26 mn; United Kingdom: +USD 21 mn; France: +USD 20 mn; Australia: +USD 15 mn; 20 other countries: +USD 64 mn; Rest of world: +USD 4.5 mn. Market value 2036: USD 1.2 bn.Market value 2026462 mnUnited States+586 mnGermany+26 mnUnited Kingdom+21 mnFrance+20 mnAustralia+15 mn20 other countries+64 mnRest of world+4.5 mnMarket value 20361.2 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • CareDx
  • Natera

Group 2: Regional and specialist players

  • Eurofins Viracor
  • Thermo Fisher Scientific
  • Chronix Biomedical

Group 3: Emerging and niche players

  • Oncocyte
  • Verici Dx

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the cell-free DNA testing transplant market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 10.0% is calculated from the resulting values.

The market is divided by organ, by testing purpose, by technology, by biomarker, by buyer. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the cell-free DNA testing transplant market?

The global cell-free DNA testing transplant market is estimated at USD 420 mn in 2025 and USD 462 mn in 2026.

How fast will the cell-free DNA testing transplant market grow?

It is forecast to reach USD 1.2 bn by 2036, a compound annual growth rate of 10.0% from 2026, an increase of USD 736 mn.

Which country is the largest market for cell-free DNA testing transplant?

United States is the largest market by revenue at USD 360 mn in 2026, 78.0% of the global total. The three largest countries together hold 85.0%.

Which country is growing fastest?

Among the ten largest markets, Brazil is growing fastest at 11.1% a year from 2026 to 2036.

Which cell-free DNA testing transplant segment is largest?

In the by organ split, Kidney is the largest segment with 66.0% of 2026 revenue.

Who are the leading cell-free DNA testing transplant companies?

Global leaders include CareDx, Natera.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Cell Therapy Centrifuge →

All Healthcare markets →

Request a sample